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PENILAIAN HASIL PENGURUSAN DIABETES DAN INTERVENSI OLEH 
AHLI FARMASI DI PULAU PINANG, MALAYSIA.  
 
 ABSTRAK 
Objektif kajian ini adalah untuk menilai dapatan pengurusan penyakit secara klinikal dan 
tanggapan pesakit terhadap keberkesanan rawatan. Kajian primer diklasifikasikan sebagai 
metodologi bercampur  dengan kajian intervensi secara rintang,yang merangkumi empat 
fasa dengan metodologi yang berbeza. Fasa I (penilaian retrospektif ), Fasa II (aplikasi 
penjagaan farmaseutikal secara prospectif), Fasa III (penilaian kajian kes secara 
prospektif ) dan fasa  IV (kajian psikometrik berasaskan populasi ).  
Terdapat 2174 pesakit diabetes yang menerima rawatan sepanjang tempoh  Januari 2008 
ke Disember 2010, dimana 2174 (100%) carta pesakit telah di teliti. Terdapat 1063 
(48.9%) pesakit lelaki dan selebihnya 1111 (51.1%) wanita. Mean dan distribusi piawai 
bagi wanita lebih rendah (35.2 ±4.187 tahun) berbanding dengan lelaki (37.9±5.724 
tahun). Sejumlah 798 (36.7%) pesakit mempunyai risiko infeksi sebelum atau semasa 
rawatan di hospital dan signifikan secara statistik sertadi dapati berkaitan dengan diabetes 
ketoacidosis (DKA) dan pendedahan terhadap jangkitan. Sebanyak 384 (48.1%) kes  
jangkitan merupakan kes berulang dalam masa 3 bulan. Terdapat 176 kes andaian 
jangkitan viral (18.2%), dan  679 kes jangkitan bakteria (70.2%).  Dari kes jangkitan 
bakteria itu, 453 kes merupakan jangkitan secara minor (66.7%), dan 226 jangkitan major 
(33.3%). 
Dalam kajian penjagaan farmaseutikal secara prospektif seramai 253 pesakit telah di 
ambil dari Klinik Pesakit Luar Hospital Pulau Pinang, yang terdiri dari pada 127 kes 
kajian  dan 126  kes kawalan. Tiada perbezaan signifikan antara kedua duanya terhadap 
xxiii 
 
sebarang variable demografik yang direkodkan. Kebanyakkan pesakit yang tua 
mengalami DM jenis 2. Intervensi tidak dilakukan dalam kumpulan kawalan 
memandangkan penyelidik tidak menilai rawatan yang dilakukan. Untuk program pesakit 
di rumah, daripada 109 subjek yang memenuhi criteria kajian, 3 subjek menolak untuk 
menyertai program ini disebabkan oleh kekurangan waktu dan minat. Keputusan utama 
kajian ini adalah berdasarkan data daripada 93 subjek yang menamatkan selama 24 
minggu (6 bulan) penyelidikan (intervensi=47, Kawalan=46). Principal component factor 
analysis telah dilakukan untuk menganalisa 10 item PSS terhadap 1924 sampel pesakit 
diabetes.  Dari jumlah tersebut, seramai 992 pesakit adalah wanita dan 932 adalah lelaki. 
Keputusan Ujian Barlett’s  adalah 1603.417 (p<0.001) dan pengukuran Kaiser-Meyer-
Olkin adalah 0.83, yang menyokong penggunaan data ini untuk analisa faktor. Analisa 
awal menghasilkan dua komponen dengan nilai Eigen melebihi 1, dengan sejumlah 59.16 
peratus untuk varians. Scree-plot inspection menjelaskan dua perkara. Rotasi Varimax 
digunakan dengan menggunapakai kedua dua faktor tersebut. Faktor A mengintegrasikan 
item item 1, 2, 3, 6, 9 and 10, dan dilabelkan sebagai “Perceived Avoidance” sementara 
faktor B terdiri dari item 4,5,7,8 dilabelkan sebagai “Perceived controllable” dalam 
Penggunaan antibiotik yang meningkat dan berulang dalam kalangan Melayu yang juga 
menunjukkan pengawalan glisemik yang kurang baik jika dibandingkan dengan bangsa 
lain. Jangkitan bakteria yang berpotensi sebagai sangat serius berlaku dalam kalangan 
sepertiga pesakit (33.3%).  
Umur didapati mempunyai kesan signifikan terhadap kadar dan jangkaan untuk mendapat 
jangkitan. Leukocytosis sering ditemui tetapi ianya lebih menunjukan tahap keterukan 
ketoasidosis dan bukannya berlaku kehadiran jangkitan. Kajian PC (Pharmaceutical Care) 
xxiv 
 
ini menjelaskan nilai khidmat seorang ahli farmasi sebagai pakar dalam\ 
menyumbangkan maklumat untuk pesakit diabetes. Ini dipanjangkan kepada CM 
(Complementary Medicines) dimana kemungkinan berlaku potensi interaksi yang tidak di 
teliti dengan sempurna. Data terkini menyarankan penilaian yang lebih besar terhadap PC 
untuk diabetes pusat penjagaan kesihatan primer.  
Skala Psychometric validation of perceived stress versi Bahasa Melayu menunjukkan 
PSS-10 merupakan alat yang boleh dipercayai untuk penilaian tekanan dalam kalangan 
pesakit diabetes dalam masyarakat. Paras tekanan yang tinggi dikenalpasti dalam 
kalangan pesakit diabetes wanita berbanding lelaki. Program penjagaan pesakit di rumah  
(PHCP) telah menunjukkan keberkesanan  program pembelajaran  yang merangkumi 
sains tingkahlaku terutama yang berkaitan dengan efikasi kendiri adalah sangat berkesan 
dalam peningkatan pengetahuan, praktis kendiri dan pengawalan glisemik dalam 
kalangan kumpulan kawalan. Penambahbaikan praktis kendiri yang memerlukan 
perubahan gaya hidup seperti perubahan pada diet dan senaman masih lagi bermasalah.  
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EVALUATION OF DIABETIC MANAGEMENT OUTCOME AND 
PHARMACIST INTERVENTION IN PULAU PINANG, MALAYSIA 
 
 
     ABSTRACT 
The objectives of the study were to evaluate clinical disease management outcome and 
patient responsiveness to treatment. The primary current study is classified as ‘mixed-
methodology’ cross sectional interventional study, which includes four phases of 
evaluation with different methodologies. Phase I (retrospective evaluation), Phase II 
(prospective pharmaceutical care application), Phase III (prospective case-control cohort 
evaluation) and Phase IV (Psychometric population based survey).  
During the time period of January 2008 through December 2010, a total of 2174 diabetes 
patients were admitted; 2174 (100%) patients’ medical profiles were reviewed. This 
comprised of 1063 (48.9%) males and rest 1111 (51.1%) females. Mean and Standard 
Distribution (SD) should females have less mean age distribution (35.2 ±4.187 years) as 
compared to males (37.9±5.724 years). A total of 798 (36.7%) had infection exposure 
before and/or during hospital admission, statistical significance (p<0.001) found in 
association of diabetes ketoacidosis (DKA) and infection exposure. Majority 384 (48.1%) 
infection type was relapsed cases within 3 months. There were 176 with presumed viral 
infection (18.2%), and 679 with bacterial infection (70.2%). Of those with bacterial 
infection, 453 had minor infection (66.7%), and 226 had major infection (33.3%). In 
prospective pharmaceutical care study, two hundred and fifty three patients from the 
Diabetes Outpatient clinic Hospital Pulau Pinang were recruited, comprising 127 cases 
and 126 controls. There were no significant differences between cases and controls for 
any of the demographic variables that were documented. The sample was predominantly 
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elderly type 2 DM patients. No interventions were made in the control group as there was 
no medication review in this group by the investigator. For patient home-care program, 
Of the 109 subject who met the study-entry criteria, 3 subjects declined to participate due 
to lack of time and interest. The primary result of this study as based on data from the 93 
subject who completed the 24-weeks (6 months) follow-up (intervention=47, 
control=46). Principal component factor analysis was done for the analysis of 10 item 
PSS dimensionality with a sample of 1924 diabetic patients. A total of 1924 diabetic 
patients with age ≥ 18 (mean age = 39.51) were approached, 992 of them were female 
and 932 of them were male. Barlett’s test of sphericity was 1603.417 (p<0.001) and 
Kaiser-Meyer-Olkin measure of the sampling adequacy was 0.83, which supported the 
use of these data in a factor analysis for further investigation. Initial analysis yielded two 
components with Eigen values exceeding 1, accumulating the total of 59.16 per cent of 
the variance. Scree-plot inspection indicated two factors. Varimax rotation was conducted 
with these two identified factors. Factor A integrated items 1, 2, 3, 6, 9 and 10, labeled as 
‘Perceived Avoidance’ while Factor B containing items 4, 5, 7, 8 and labeled as 
‘Perceived Controllable’. Increased and recurrent use of antibiotic was found among 
Malays. Malays predominantly experienced poor glycaemic control as compared to other 
races.  
Major bacterial infections with potential serious sequel are particularly common (33.3%), 
as every third patient being presumed to have serious consequences. Age has a significant 
effect on the rate and prediction of infection. Leukocytosis is commonly found but more 
likely reflects the severity of ketoacidosis rather than the presence of infection. The PC 
study highlights the value of the pharmacist as an information resource for patients with 
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diabetes. This extends to CMs where potential interactions with conventional therapy 
may be neither suspected nor recognized. The present data may suggest that a larger 
evaluation of a PC program for diabetes in the primary care setting may be valuable. 
Psychometric validation of perceived stress scale in Malay version shows that the PSS-10 
is a reliable tool for assessing the stress measures among diabetic living of the society. 
Female diabetic patients were identified to experience high stress level as compared to 
male patients. Patient home-care program (PHCP) has shown a brief structured education 
program that incorporated behavior science specifically self-efficacy was effective in 
enhancing knowledge, some of the self-care practices (SMBG and medication adherence) 
and improving glycaemic control in the intervention group. Improvement of self-care 
practices that require lifestyle changes such as diet and increased in physical activities are 
problematic. 
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     CHAPTER 1 
     INTRODUCTION 
The prevalence of diabetes is on the increase and an estimated 239 million people worldwide are 
expected to have the condition by the year 2020 (Patel A, 1999). Diabetes mellitus (DM) 
represents a serious health care challenge. It is a heterogeneous disorder characterized by varying 
degrees of insulin resistance and insulin deficiency, which leads to disturbances in glucose 
homeostasis. It is commonly associates with prolonged ill health and premature death (Douglas 
et al., 1998). The mortality rate in patients with DM may be up to eleven times higher than in 
persons without the disease (Florence & Yeager, 1999; UKPDS, 1998). DM is the leading cause 
of blindness, renal failure and foot and leg amputations in adults in developed countries (Patel A, 
1999).  
 
The World Health Organization (WHO) classification system of DM recognized two major 
forms of diabetes (King H et al., 1993); 
1. Type 1 diabetes mellitus (DM), formerly known as insulin dependent diabetes mellitus 
(IDDM; patient is dependent on exogenous insulin for survival) 
2. Type 2 DM, formerly known as non-insulin dependent diabetes mellitus (NIDDM; patient is 
not necessary dependent on exogenous insulin for survival). 
Teamwork and collaboration are essential components of successful DM management, both to 
prevent complications and maintain the patients’ health-related quality of life (HRQOL) over a 
lifetime of coping with the disease (Patel A, 1999). 
 
2 
 
Type 1 DM is characterized by insulin deficiency resulting from immune-mediated pancreatic 
beta-cell destruction. The most serious acute consequence of this is ketoacidosis. Pancreatic beta-
cell destruction eventually results in absolute insulin deficiency (Patel A, 1999). Type 1 DM 
accounts for approximately ten percent of all DM cases in the world population. Type 2 DM is 
generally characterized by peripheral insulin resistance with relative insulin deficiency to 
predominant insulin secretory defeat with insulin resistance (Patel A, 1999). Type 2 DM 
accounts for approximately ninety percent of all DM cases.  
 
The major risk factors in the development of type 2 DM are (Florence & Yeager, 1999); 
1. Family history 
2. Obesity 
3. Race/raceity 
4. Increasing age (especially greater than forty five years) 
5. Previous identified impaired fasting glucose or impaired glucose tolerance 
6. Hypertension  
7. Hyperlipidemia 
8. History of gestational DM 
  
There is evidence that good glycaemic control can slow or prevent the development of diabetes 
complications (Miller M, 1996; Keen H, 1998; UKPDS, 1998; Turner et al., 1998; Stratton et al., 
2000). The Diabetes Control and Complication Trial (DCCT) demonstrated the association 
between the degree of glycaemic control and the development of microvascular complications in 
type 1 DM patients (DCCT, 1993; DCCT, 1996). The DCCT determined that there was an 
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approximately 50% reductions in microvascular complications in the intensive treatment group 
and a non-significant tendency to fewer major cardiovascular events. Intensive control was 
accompanied by a significantly between the groups. The DCCT investigators did advice caution 
in extending the findings to patients with type 2 DM regardless to age and coexisting diseases. 
 
The DCCT was an important study, due to the relatively large number of patients included and 
the long followed-up period. The entire cohort of 1441 patients was followed for a mean of six 
and half years. Primary and secondary prevention cohorts were included. The care in the 
intensive group was carried out by an expert team of dialectologists, nurses, dieticians and 
behavioral specialists, and the time, effort and cost involved was considerable. It is important to 
note that the resources used in the intensive group are not widely available and the DCCT 
investigators suggested that new strategies were needed to adapt methods of intensive treatment 
for use in the general community in an efficient and cost effective way. 
 
The United Kingdom Prospective Diabetes Study (UKPDS) was the largest scale long-term 
intervention study in newly diagnosed type 2 DM patients and involved over 5000 patients. The 
UKPDS used an intensive blood glucose control policy, which achieved a medium HbA1c of 7% 
compared with 7.9% in those randomized to conventional treatment over a median 10 years 
follow-up (Stratton et al., 2000). The UKPDS confirmed the benefit of intense glycaemic control 
on microvascular disease in type 2 DM patients(UKPDS 17, 1996; UKPDS 23,1998; UKPDS33, 
1998; UKPDS 34, 1998; UKPDS 37, 1998, UKPDS 39, 1999). The complications of type 2 DM 
and the treatment with preventions of these complications, especially with respect to 
pharmacotherapy, are discussed in following section. 
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1.1 COMPLICATIONS & TREATMENT OF TYPE 2 DIABETES MELLITUS  
1.1.1 Microvascular complications 
Complications such as retinopathy, nephropathy and peripheral neuropathy can lead to blindness, 
renal failure and limb amputations respectively (Patel A, 1999). The DCCT (DCCT, 1993; 
DCCT 1996) and the UKPDS (UKPDS 34, 1998; UKPDS 37, 1998, UKPDS 39, 1999) have 
demonstrated an association between microvascular complications and glycaemic control in both 
type 1 and type 2 DM patients. 
 
1.1.1.1 Nephropathy 
Nephropathy develops in approximately twenty percent of persons with type 2 DM. Its earliest 
manifestations in microalbuminuria (urine albumin creatinine ratio (ACR) ≥3mg/mmol). Within 
10 years of diagnosis of type 2 DM, one third of patients will have macroproteinuria and 0.6% 
will have features of renal failure (Miller M, 1996; Bloongarden ZT, 1999). In patients with type 
2 DM, microalbuminuria is also associated with an increase in cardiovascular mortality 
(Spelstra-de Man et al., 2000; Valmarid et al., 2000; Capes SE et al., 2000). 
 
Gaede, 1999 found that intensive intervention in type 2 DM patients can reduce the progression 
of nephropathy. The study was a randomized, open, parallel trial (n=149) conducted to determine 
whether intensive multifactorial, intervention that included changes in behavior and 
pharmacological management, slowed the initiation and progression of microvascular 
complications in patients who have microalbuminuria and type 2 DM. The HbA1c level at 
baseline for the standard treatment group was 8.8±1.7% and for the intervention group 8.4±1.6% 
after the four year period the results were 8.6±1.9% and 7.6±1.6% respectively (p<0.05, across 
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time and between groups). Physician, nurse and dietician provided the intensive intervention for 
the cases. Some of the treatment goals are provided in Table 1.1. 
Table 1.1: Multifactorial intervention in patients with type 2 DM; treatment goals in standard and 
intensive group – (Gaede, 1999). 
Intervention  Standard 
group 
n=76 
Intensive 
group 
n= 73 
Systolic blood pressure (SBP) mm Hg 
Diastolic blood pressure (DBP) mm Hg 
Glycosylated haemoglobin (HbA1c) % 
Angiotension converting enzyme (ACE) inhibitor 
Irrespective of blood pressure (BP) 
Aspirin to patients with ischaemic heart disease (IHD) 
Aspirin in patients with peripheral vascular disease 
Triglycerides (mmol/L) 
Total cholesterol (mmol/L) 
High density lipoproteins (HDL)-Cholesterol (mmol/L) 
<160 
<95 
<7.5 
No 
 
Yes 
No 
<2.2 
<6.5 
>0.9 
<140 
<85 
<6.5 
Yes 
 
Yes 
Yes 
<1.7 
<5.0 
>1.1 
   
This study was collectively on small sample size and demonstrated that intensive multifactorial 
intervention in patients with type 2 DM and microalbuminuria slowed the progression of 
nephropathy, as well as progression of retinopathy and autonomic neuropathy. This study was 
not designed to assess which aspect of the multifactorial intervention resulted in the results seen, 
but highlighted the need for intensive intervention in type 2 DM patients to see clinically 
relevant improvement in diabetes control. 
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Various treatments have been investigated to determine whether pharmacological intervention 
can slow the progression of nephropathy, in particular ACE inhibitor (Taguma et al.,, 1985; 
Bauer et al.,, 1986; Kefleher C, 1990; Mathiesen et al.,, 1991; Sano et al., 1994; Alimad et al.,, 
1997; Adler A et al., 2000). Some of these studies concluded that the reduction in 
microalbuminuria seen with ACE inhibitors could not be simply attributed to good BP control ( 
Cahn J et al., 1992; Goa K, Haiia M, Wilde M, 1997), while others, including the findings of the 
UKPDS-39 concluded that the suggestion to ACE inhibitors have a specific renal protective 
effect in the treatment of type 2 DM is not supported. There was some controversy over the role 
of ACE inhibitors in slowing the progression of nephropathy until 2000, when the Heart 
outcomes Prevention Evaluation (HOPE) study found that the ACE inhibitor ramipril provided 
nephroprotection (HOPE, 2000; Sleight P, 2000). This benefit was independent of ramipril’s 
effect on BP and was determine in over 3000 people. The HOPE study was a landmark study and 
solved the controversy surrounding ACE inhibition and DM. The use of ACE inhibitors in DM 
patients is now considered standard therapy (Pahor M et al., 2000; Lovell H, 2003). The HOPE 
2000 study concluded that, the treatment represents a vasculoprotective and renoprotective effect 
for people with diabetes. Angiotension receptor II (ARII) blockers have also been shown to slow 
the progression of nephropathy in patients with type 2 DM (Lewis EJ et al., 2001; Parving H et 
al., 2001). Like ACE inhibitors, the renoprotective effect appears independent of the drugs 
ability to lower BP. 
 
Management of patients with microalbuminuria and/or nephropathy must also focus on good 
glycaemic control, good BP control, lowering of cholesterol levels where necessary and 
cessation of smoking (Patel A, 1999; Nathan DM, 1998). 
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  1.1.1.2 Neuropathy 
The manifestations of neuropathy in DM are extensive (Patel A, 1999). Abnormalities can be 
detected in most patients who have had DM for five to ten years. Peripheral neuropathy can 
cause sensory loss in the feet and legs resulting in the loss of protective sensation in the feet 
(Patel A, 1999). Other symptoms include impotence, gastrointestinal dysfunction, lack of 
sweating in the feet, resting tachycardia and a fall in SBP on standing. Good glycaemic control to 
slow the progression of neuropathy in paramount (UKPDS 33, 1998). 
 
  1.1.1.3 Retinopathy 
Globally retinopathy is seen in about 15% of patients who have had DM for more than 15 years. 
In the Australia and the United States of America (USA), DM is the leading cause of blindness 
(Patel A, 1999). Microangiopathy affecting the retina develops over a number of years. Vision is 
not affected by all retinopathies, but regular review is important for controlling the condition and 
maintaining vision. All patients with diabetes should receive ophthalmologic examinations at 
least annually (Patel A, 1999). Good glycaemic control is the key to slowing the progression of 
retinopathy (Stratton et al., 2000). 
 
 1.1.2 Macrovascular complications 
Type 2 DM usually presents as part of a syndrome of metabolic abnormalities, which include 
hyperglycemia, central obesity, dyslipidemia, hypercoagulation, hypertension and insulin 
resistance (Patel A, 1999). Type 2 DM is associated with a two to three fold increased risk of 
cardiovascular morbidity and mortality and an increased risk of developing congestive heart 
failure (Miller M, 1996; Fagan & Sowers, 1999). The relative risk of stroke in patients with 
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diabetes is also increased 2 to 3 fold. Aggressive antihypertensive therapy and routine 
anticoagulation therapy for atrial fibrillation may reduce the risk of stroke (Davis et al., 1999). In 
addition to stroke, treating hypertension in persons with DM reduces other cardiovascular 
endpoints (Adler A et al., 2000).  
 
Several potentially modifiable risk factors for coronary heart disease (CHD) in type 2 DM 
patients have been identified (UKPDS 33, 1998). The risk factors include hyperglycemia, 
hypertension, dyslipidemia and smoking.  
 
  1.1.2.1 Hyperglycemia 
Dietary and lifestyle modification are the first line intervention in all type 2 DM patients unless 
the patient is acutely unwell. It is usual to institute dietary management for the first three months 
following diagnosis and then reassess blood glucose level (Patel A, 1999). The nutritional goals 
for people with DM are similar to those for a healthy diet in the non-diabetic population with the 
aim of attainting and maintaining good control of blood glucose, lipid and BP. The dietary 
modifications in type 2 DM patients must involve weight reduction in those patients who are 
overweight or obese. Type 2 DM patients should be encouraged to reduce the intake of refined 
carbohydrate (sugar) and fats in favor of unrefined carbohydrates, so that the latter makes up at 
least half of the patient’s total energy intake (Patel A, 1999). A wide variety of foods should be 
included in the diet, with particular emphasis on food containing a high proportion of dietary 
fibers. As well as being generally beneficial, dietary fiber may retard the absoption rate of sugars 
in the diet, and aid in glycaemic control (Brown A, 1998). When dietary management succeeds, 
the benefits are undisputed. Blood pressure, lipids and BP falls and life expectancy may be 
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prolonged by three to four months for each kilogram lost during the first year of treatment 
(Williams O, 1994). However, dietary compliance over long periods tends to be poor (Wing & 
Anglin, 1996; Foreyt & Poston, 1999). 
 
Lifestyle changes must include appropriate levels of exercise (minimum of 30 minutes three 
times a week; ideally 30 minutes daily), minimization of alcohol intake and cessation of smoking 
(Ponte C, 1996). Most patients with type 2 DM have a reduced functional capacity for exercise 
and a through physical assessment (with special reference to CHD) is recommended before the 
patient begins any exercise program. The exercise program should normally begin slowly and the 
need for persistence should be emphasized (Ponte C, 1996). However, permanent lifestyle 
changes are difficult to achieve (Wing & angling, 1996; Foreyt & Poston, 1999). 
 
The American Diabetes Association (ADA) recommends that action should be taken in the type 
2 DM patient whose fasting plasma glucose (FPG) concentration exceeds 7.8mmol/L and the 
HbA1c value is more than 8% (Mensing C et al., 2000). The target should be FPG <6.7 mmol/L 
and HbA1c < 7% (Bailey & Turner, 1996). These targets may be achievable in the early stages 
of the disease but become more difficult to achieve as the disease progression. Drugs available to 
maintain glycaemic control include metformin, sulphonyluria, Acarbose, insulin, meglitinides 
and the thiazolidinediones.  No study to date has determined the drug regimen of choice for type 
2 DM (UKPDS 33, 1998; UKPDS 34, 1998; Turner et al., 1999; Stratton et al., 2000). The main 
translatable finding of the UKPDS is that intensive therapy for type 2 DM is beneficial (Nathan 
DM, 1998). It is also estimated that a two percent reduction to HbA1c over a four-year period 
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would be associated with significant decrease in proliferative retinopathy and sensory 
neuropathy in patients with type 2 DM ((Miller M, 1996). 
 
   1.1.2.1.1 Metformin 
    1.1.2.1.1.1 Mechanism 
Metformin is a biguanide that may reduce glucose absorption from the intestine, increase uptake 
of glucose into the tissues from the blood, reduce liver production of glucose and reduce insulin 
requirements for disposal of glucose. It has no effect on insulin resistance (Baily CJ, 1992; 
Baliga & Fonseca, 1997). Metformin can be used either in initial therapy, as add-on therapy 
when sulphonylurea alone has failed and diet and exercise are no longer maintaining appropriate 
blood glucose levels, or in combination with insulin therapy (Bailey & Turner, 1996). Metformin 
and sulphonylurea cause similar reduction in FPG concentrations in patients with type 2 DM 
(Mensing C et al., 2000).  
 
    1.1.2.1.1.2 Features of metformin and place in therapy 
Metformin decreases appetite, can promote weight loss and has a beneficial effect on serum 
lipids. Reductions in triglyceridaemic individuals with type 2 DM can be up to fifty percent 
(Bailey CJ, 1992). Metformin does not usually induce hypoglycemia because metformin has an 
antihyperglyceamic action rather than the hypoglycaemic actions typical of sulphonylureas and 
insulin. Metformin is often be preferred as initial therapy in the obese patient because it promotes 
weight loss (UKPDS-34, 1998). The features of metformin and its place in therapy is presented 
in Table 1.2 (Moses et al.,1999; stang M, Wysowski DK, dutler-Jones, 1999; Anonymous, 2003) 
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Table 1.2 Metformin: features and place in therapy  
Variable Comment 
Type of therapy 
 
 
Indications 
 
 
 
Tablet sizes 
Dose range 
 
Treatment schedule 
 
Contraindication 
 
 
Side Effects 
 
 
 
Bioavailability  
Blood concentration 
 
Blood half-life 
Metabolism 
Elimination 
Monotherapy; combination therapy with a sulphonylurea or a 
meglitinide, combination with insulin, combination with a 
thiazolidinedione 
After failure of diet and exercise in type 2 DM, especially in 
overweight patients. After failure with sulphonylureas, 
combination therapy with insulin, combination with a 
thiazolidinedione 
500mg, 850mg and 1gm 
250mg – 3gm in daily divided doses (maximal effect is seen at 
doses of 2 gm daily) 
Taken with meals, increase dose slowly, maximum dose 3 gm 
daily 
Moderate to severe renal or hepatic disease, cardiac or 
respiratory insufficiency, any hypoxic conditions, severe 
infections, alcohol abuse, history of lactic acidosis, pregnancy 
Gastrointestinal symptoms and metallic taste, may impair 
absorption of vitamin B12 and folic acid (rarely causes 
deficiencies), Hypothetical risk of lactic acidosis with listed 
contraindications 
50-60% 
Maximal 1-2 hours after oral dose, negligible binding to blood 
proteins 
1.5-4.9 hours 
Not measurably metabolized 
Ninety percent eliminated in the urine in twelve hours. 
 
Metformin has been shown to lower both FPG levels and HbA1c in moderately obese patients 
with type 2 DM who were inadequately controlled by diet (DeFronzo RA, 1999). The primary 
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failure rate for metformin is reported to be 5-20% but this includes who discontinue the drug 
because of initial gastrointestinal side effects. Secondary failures are reported to be five to ten 
percent per year which is similar to sulphonylurea (Bailey C & Turner R, 1996). The data from 
UKPDS indicate that metformin is as effective as insulin or sulphonylurea therapy in decreasing 
both FPG levels and HbA1c, without causing weight gain, hypoglycemia or hyperinsulinaemia 
(Turner, Cull & Holman, 1996). The UKPDS-34, 1998 showed that among overweight patients 
allocated intensive blood glucose control, metformin showed a greater effect that sulphonylureas 
or insulin for any DM related endpoint, all-cause mortality and stroke. Early addition of 
metformin in sulphonylureas treated patients was associated with an increased risk for diabetes-
related deaths and all-cause mortality in over-weight patients (both subsets of patients were 
reviewed separately and together). The reason for this increased risk is currently unknown and 
requires further study to clarify the place of metformin and sulphonylureas in the treatment of 
type 2 DM. Overall, metformin does seem to be advantageous as a first-line pharmacological 
therapy in diet-treated over-weight patients with type2 DM. it can also be used first-line in 
normal weight type 2 DM patients (UKPDS 34, 1998, UKPDS 39, 1999). 
     
1.1.2.1.1.3 Side effects 
Metformin has a tenfold lower risk of lactic acidosis than its predecessor phenformin (Arc, 
Korhonen T, Halinen, 1978). Metformin should be used with caution in patients with any risk 
factors that may precipitate lactic acidosis, such as moderate to severe renal failure, although 
evidence for this is mainly from case reports. Diarrhoea is a common side effect of metformin 
and may limit its use (Bailey & Turner, 1996). This is side effect can be minimized by starting at 
a low dose (250 mg to 500mg daily) and slowly titrating upwards according to FPG results. 
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Long-term therapy with metformin is associated with decreased intestinal absorption of 
cyanocobalamin and folate, but anaemia has developed in few patients (Bailey & Turner, 1996). 
    1.1.2.1.1.4 Potentially significant drug interactions 
Renal clearance of metformin may be reduced by concurrent administration of cimetidine 
(Somogyl A et al., 1987). The proposed mechanism is competition between cimetidine and 
metformin for proximal tubular secretion. If cimetidine is introduced to a patient on a stable dose 
of metformin, the patient should monitor the blood glucose closely.  
   1.1.2.1.2 Sulphonylureas 
    1.1.2.1.2.1 Mechanism 
The mechanism of action is currently thought to be beta cell receptor specific stimulation of 
insulin release from the pancreas, thereby increasing circulating levels of insulin (Lubbo, Miller 
& Rose, 1995). There is evidence that insulin levels fall over the ensuring months or years after 
commencing therapy, although the drugs often retain their effectiveness as hypoglycemics. 
Sulphonylureas may also have effects on reducing glucose production in the liver and increasing 
glucose uptake by skeletal muscle cells (Brown A, 1998), although these effects are relatively 
minor. 
    1.1.2.1.2.2 Place in therapy 
The UKPDS, 1998 showed that intensive blood-glucose control by either sulphonylureas or 
insulin substantially decreased the risk of microvascular complications, but not macrovascular 
diseases. An intensive blood-glucose control policy was associated with an average HbA1c of 
7.0% over the duration of the study compared with 7.9% in conventionally managed patients. 
Sulphonylreas are generally used in type 2 DM patients who do not respond to diet alone, do not 
require insulin and are not obese (Florence & Yeager, 1999). Sulphonylureas are contraindicated 
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in severe insulin deficiency, pregnancy, in intercurrent illness, and in perioperative patients 
(because of their prolonged hypoglycemia). How long sulphonylureas remain effective cannot be 
predicted, and patients must be reviewed regularly (Williams O, 1994). Approximately two third 
of patients who begin therapy with a sulphonylureas respond, although depending on glycaemic 
targets, twenty percent or more eventually require additional therapy (Ponte C, 1996). There are 
several identified causes of secondary failure in patients receiving sulphonylureas. These include 
addition of drugs causing hyperglycemia, non-adherence to dietary requirements or drug therapy, 
stressors (CHD, infection, surgery, thyrotoxicosis, trauma) and/or weight gain (Ponte C, 1996). 
A list of common used sulphonylureas is listed in Table 1.3 (Baliga & Fonseca, 1997; Anonyous, 
2003; Yeap BB, 2001). 
Table 1.3 Characteristics of sulphonylureas  
Agent  Daily dose  Tablet strength Duration of 
effect 
Half life  
Gibenclamide 5mg(elderly 2.5mg); 
max 15 mg 
2.5mg and 5 mg 20-29 hours 10 hrs (longer in 
impaired renal 
function) 
Gliclazide 40-80mg; max 
320mg (divided 
doses) 
30-90mg (single 
dose) 
80 mg 
 
 
30mg MR* 
10-15 hrs 
 
 
24 hrs 
6-15 hours 
Glipizide 205-5mg; max 
40mg (divided dose) 
5 mg 14-16 hrs 1-5 hours 
Glimepiride 1-8mg daily (single 
dose) 
1,2,3 and 4 mg 24 hrs 5 hours 
*MR= Modified release 
    1.1.2.1.2.3 Pharmacokinetics 
Sulphonlyureas are almost completely absorbed following oral administration. The rates of 
absoption, biotransformation and duration of action differ for each compound. They are 
metabolized by the liver and excreted predominantly in the urine. Glibenclamide is a typical long 
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acting agent, which is excreted as metabolites in the bile and urine (Riddle M, 2000). Due to an 
enhanced risk of accumulation, this drug should be avoided in patients with moderate to severe 
renal disease in favor of an agent that is solely hepatically metabolized, such as gliclazide. 
  
    1.1.2.1.2.4 Significant drug and food interaction 
Many drugs interact with sulphonylureas and may interfere with diabetes control (William O, 
1994). Important interactions include aspirin and sulphonamides. A study in which high dose 
aspirin was introduced to glibenclamide therapy resulted in an increase in the free fraction of 
glibenclamide and potential hypoglycemia (Kubacka et al., 1996). Patients on low dose aspirin 
did not experience this effect. Patients on stable sulphonylurea therapy should be counseled to 
take paracetamol for pain, rather than aspirin as high dose aspirin may cause hypoglycemia. The 
literature has varying reports concerning non-steriodal anti-inflammatory drugs (NSAID) and 
sulphonylureas; the interaction is probably not of clinical significance at standard doses (Lubbos, 
Miller & Rose, 1995). Introduction to sulphonamides to stable sulphonylurea therapy can cause 
severe hypoglycemia. This interaction is more significant with the longer acting sulphonylureas 
(Wing & Miners, 1985; Hansen & Kristensen, 1991).  
 
Alcohol blocks gluconeogenesis and the surge in hepatic glucose output, that is crucial for 
recovery from hypoglycemia and may subsequently cause hypoglycemia, in patients on 
sulphonylureas. Average amount of alcohol (< 2 standard drinks per day for a male) should not 
cause a problem, but consumption of large amounts of alcohol or binge drinking may precipitate 
hypoglycemia (Riddle M, 2000). There are case reports of patients developing hypoglycemia 
with concurrent administration of glibenclamide and ACE inhibitors (Arauz el al.,1990). The 
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proposed mechanism of action is increased insulin mediated removal of glucose in skeletal 
muscle and tissues via a vasodilatory action of ACE inhibitors. When patients on stable 
sulphonylureas therapy are commenced on an ACE inhibitor they should be informed that 
sudden hypoglycemia has been reported and that they should monitor their blood glucose levels. 
 
Concurrent administration of some antacids containing magnesium hydroxide may increase the 
rate of absorption of some sulphonylureas (Kivisto & Neuvonen, 1991; Self T, Tsiu, Fowler, 
1992). Patients should be counseled to separate administration of antacids and sulphonylureas by 
two hours to avoid potential hypoglycemia. 
 
Rifampicin induces hepatic metabolizing enzymes and longer doses of some sulphonylureas may 
be required to control blood glucose levels during concomitant therapy (Self T, Tsiu S, Fowler S, 
1992). When the rifampicin is ceased the doses must be reduced to prevent hypoglycemia. There 
are many other reported interactions in the literature between sulphonylureas and other drugs but 
most have unproved clinical relevance. Introduction of a new drug to a patient on stabilized 
sulphonylurea therapy warrants an increase in frequency of blood glucose monitoring and 
appropriate counseling of the patient. 
    1.1.2.1.2.5 Side effects 
The main side effects of sulphonylureas are nausea, epigastric fullness, heartburn, hypoglycemia, 
hyperinsulinanemia, weight gain and liver enzyme elevations. Sulphonylureas act via 
endogeneous insulin and their main side effects of hypoglycemia and weight gain are generally 
predictable and dose related. Hypoglycemia, although relatively uncommon, may be severe and 
difficult to reverse (Ponte C, 1996). Certain risk factors may dispose a patient to hypoglycemia 
17 
 
episodes and these include increased age, renal dysfunction and decreased energy intake (Den-
Ami el al.,1999). Enhanced therapeutics monitoring may be warrant in patients with the above 
risk factors. 
 
Skin rashes can occur with sulphonylureas. Sulphonylureases are chemically related to 
sulphonamides but do not share the same pharmacological adverse effect profile. Severe 
hypersensitivity reactions (e.g, blood dyscrasias and Stevens Johnson syndrome) are rare (Brown 
A, 1998). 
 
   1.1.2.1.3 Acarbose 
Acarbose is an alpha-glucosidase enzyme inhibitor and can diminish postprandial blood glucose 
by delaying carbohydrate absorption from the small intestine (UKPDS 44, 1999). It is a useful 
addition to other oral treatments for lowering blood glucose, especially if insulin may not be 
desired or is inappropriate. Careful titration of the dose of acarbose is necessary to minimize side 
effects. The starting dose should be 25 mg taken at the beginning of each meal. The dose can be 
increased every four to eight weeks, depending on response. Doses greater than 300 mg should 
not be required (Patel A, 1999). 
 
There are significant compliance problems with acarbose due to high incidence of flatulence and 
diarrhea and the necessity to take acarbose three times a day for maximum benefit. A 
randomized double blind trial showed that acarbose significantly improved glycaemic control 
over three years in patients with type 2 DM, irrespective of concomitant therapy (UKPDS 44, 
1999). In patients who continued to take acarbose for the full three years a reduction in HbA1c of 
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0.5% was seen. This may be a clinically relevant reduction in HbA1c, as acarbose is used in 
combination with other agents and may be added to avoid progression to insulin therapy. 
 
Acarbose alone does not cause hypoglycemia but, when used in combination with a 
sulphonylurea, hypoglycemia may result. The hypoglycemia caused by this combination cannot 
be treated with oral carbohydrates because acarbose delays its absorption. Patients on acarbose 
should use glucose tablets, glucose liquid or glucagon injections for the treatment of 
hypoglycemia (Bohannon N, 1996). Acarbose is used for type 2 DM patients whose blood 
glucose concentrations are inadequately controlled despite diet, exercise and maximal tolerated 
doses of other oral anti-diabetic agents, and where insulin therapy is inappropriate (Anonymous, 
2003). 
   1.1.2.1.4 Thiazolidinediones 
These drugs have been described an insulin sensitizers because they have been shown to enhance 
glycaemic control, lower insulin levels and promote glucose utilization in the tissues. They do 
not cause hypoglycemia, weight gain or lactic acidosis (Anonymous, 1998). The currently 
available thiazolidinediones or glitazones are pioglitazone and rosiglitzaone, and these drugs 
have been recently listed to use in treatment therapy (Anonymous, 2003). 
About 40 cases of serious hepatic dysfunction were reported with the use of troglitazone, 
including rarely, severe hepatocellular damage, hepatic necrosis and hepatic failure (Plosker & 
Faulds, 1999). Among troglitazone patients who started treatment in 1998, the estimated risk of 
liver-related death was approximately 1 in 100,000 (Juhi el al., 2000). Troglitazone has 
subsequently been withdrawn from the market. The level of liver dysfunction seen with 
troglitazone has not been demonstrated with the newer glitazones, but vigilance is required. 
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Liver function tests should be performed regularly and the thiazolidinedione should be 
discontinued in the presence of unexplained deterioration of liver function (Plosker & Faulds, 
1999). 
   1.1.2.1.5 Meglitinides 
Meglitinides, such as repaglinide act as prandial glucose regulator (Juhi el al.,2000). Repaglinide 
is short acting with a rapid onset of effect and should be taken shortly before a meal. It should 
not be taken if the meal is missed. Long-term glycaemic control is similar to that seen with 
sulphonylureas and the tolerability profile is also similar (Anonymous, 1998). Repaglinide is not 
listed to used in Australia and UK for the therapeutic treatment and rarely use in clinical 
practices (Anonymous, 2003).  
   1.1.2.1.6 Insulin 
Over the long natural history of type 2 DM, up to 30% of patients eventually fail to respond to 
oral agents and require insulin (Turner el al.,1999; Yeap BB, 2001). The decision to start insulin 
is dependent on many factors including age, complication, symptoms, concomitant diseases and 
overall life expectancy. Increased hepatic output of glucose, especially at night, is the main 
determinant of fasting hyperglycemia in patients with type 2 DM (Baliga & Fonseca 1997). The 
bedtime administration of an intermediate acting insulin can be very beneficial as this may 
improve glycaemic control through only one injection a day. In some cases, patients who are 
falling oral therapy are switched to a multiple-insulin injection regimen similar to that given to 
type 1 DM patients (Ragucci, zonsein & Frishkan, 2003). Commonly, type 2 DM patients may 
be given twice daily subcutaneous injections of premixed short and intermediate insulins (Yeap 
BB, 2001). There is no standard dose of insulin and requirements depend on many factors such 
as diet, weight, exercise levels, stress and illness (Bryant, Knights, Salerno, 2003). Each patient’s 
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needs must be determined individually and may change on a day-to-day basis and over the 
course of the disease. A typical daily dose might be in the order of 0.5-0.7 units/kg/day split into 
1-4 injections and possibly 2 or 3 different types of insulin. Treatment schedules need to be 
reviewed regularly and adjusted as necessary (Bryant, Knights, Salerno, 2003). The UKPDS 
1998 showed that intensive blood glucose control whether by insulin or oral therapy 
substaintially decreased the risk of microvascular complications. Exogeneous insulin has been 
suggested as a potentially harmful treatment because in-vitro studies with raised insulin 
concentration induced atheroma. The UKPDS 1998 did not find any evidence of this, while 
intensive blood glucose control does have some disadvantages in that risk of hypoglycemia and 
weight gain is higher. A simple treatment algorithm for the management of type 2 DM is 
presented in Figure 1.1. 
  1.1.2.2 Dyslipidemia 
Aggressive treatment of dyslipidemia in DM is essential (Golomb &Criqui, 1999; Herman et al., 
1999). Plasma cholesterol is an independent risk factor for CHD and the risk is higher in people 
with DM than in the non-diabetic population (Patel A, 1999). Determination of the lipid profile 
(total cholesterol, triglycerides, low density lipoproteins (LDL) and HDL-cholesterol) should 
form a part of the annual assessment of the diabetic patient. Targets of patient with diabetes 
should include reaching a total  cholesterol of < 4.0 mmol/L, LDL-cholesterol of <2.5 mmol/L, 
HDL-cholesterol of > 1.0mmol/L and triglycerides of < 2.0 mmol/L (Guidelines, 2003).  
Emphasis needs to be placed on weight reduction, exercise and restriction of saturated fat, 
cholesterol, sugar, sodium chloride and alcohol. The efficacy and tolerability of the 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors or statins, puts them as first-line 
therapy for hypercholesterolaemia (Montori et al., 2000). Simvastatin, pravastatin, fluvastatin 
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and atorvastatin are currently available worldwide for treatment (Anonymous, 2003). For 
patients who cannot tolerate statins or need combination therapy fibrates are a useful alternative 
(Guideline, 2003). Of the fibrates, gemfibrozil and fenofibrate are listed options. Fenofibrate is 
only available via clinical trials. A recent quantitative systemic review has also confirmed that 
fish oil supplement (containing omega-3 fatty acids) in type 2 DM lowers triglycerides (Montori 
et al., 2000). The review did emphasize that further research was needed into the use of fish oil 
in type 2 DM, however they may provide a useful alternative or addition to DM patients with 
raised triglycerides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Management of type 2 DM in Malaysia (Montori et al., 2000) 
Target glycosylated haemoglobin  
< 7% 
Assessment of glycaemic control 
Home blood glucose monitoring 
Glycosylated haemoglobin (3 monthly) 
Drug therapy for type 2 DM 
Re-enforce compliance 
Commence metformin 
(Especially for obese type 2 DM patients) 
Weight reduction, Dietary 
modification, Exercise 
 
Add Sulphonylurea 
Consider further options 
+/ - referral to an endocrinologist 
Insulin therapy Repaglinide Glitazone Acarbose 
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  1.1.2.3 Hypertension 
The development of stroke and microvascular disease in patients with DM is related to 
hypertension. Tight control of BP in hypertensive patients with type 2 DM substantially reduced 
the cost of complications, increased the interval without complications, increased survival, and 
had a cost effectiveness ratio that compared favorably with accepted healthcare programs 
(Mogensen CE, 1998; UKPDS, 1998). Hypertension in DM also responds well to weight loss 
and exercise (Chobanian et al., 2003).  
 
The UKPDS-38, 1998 found that tight control of BP reduced death caused by DM by 32%. The 
hypertension in diabetes study was a multicentre, controlled trial embedded within the UKPDS 
that was designed to determine whether tight BP control (less than 150/85 mmHg), reduced 
morbidity and mortality in hypertensive patients with type 2 DM, compared to less tight control. 
Of the 4297 patients recruited to UKPDS, 1544 (38%) had hypertension (defined as a BP > 
160/90 mmHg or antihypertensive therapy) and, of these, 1148 were eligible for the hypertension 
in Diabetes study. Recruitment ran over a four-year period. Patients visited study clinics every 
three to four months and BP was measured and adjustments to medications were made where 
necessary and appropriate. The median follow up to the end of the trial was 8.4 years. Patients 
allocated to tight BP control compared with less tight control had a 24% reduction in risk of 
developing any end point related to diabetes (p = 0.005). Tight BP control also resulted in a 
reduction of 44% for stroke, 56% for heart failure and 37% for microvascular disease. UKPDS 
suggested the goal with BP reduction could be as low as SBP < 135 mmHg and DBP < 
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85mmHg. The UKPDS achieved a mean BP of 144/82 mmHg in the tight control group. The 
UKPDS-38, 1998 concluded that  
“Tight control of BP achieves a clinically important reduction in the risks of deaths related to 
DM, complications related to DM, progression of diabetes retinopathy, and deterioration in 
visual acuity”. 
While it is clear that lowering BP is important with diabetes, optimal treatment of hypertension 
in DM continues to be controversial. The currently recommended goal in clinical management is 
a BP of 135/85 mmHg or lower (Mogensen CE, 1998; Nosadini R et al., 1998). Recently, the 
results of the antihypertensive and lipid-lowering treatment to prevent heart attach trial 
(ALLHAT) (ALLHAT, 2002) concluded that thiazide diuretics were the preferred first-line 
treatment, in non-diabetic patient. Subgroup analyses of comparative trials, including the 
ALLHAT trial, have demonstrated no advantage of ACE inhibitors over thiazides in people with 
DM and no renal disease (Anonymous, 2003). The results of the Second National Blood Pressure 
Study (Wing, Reid & Ryan, 2003) contradicted the results of ALLHAT and concluded that 
treatment with ACE inhibitors leads to better outcomes than treatment with diuretics.  
The controversies will continue to persist but it would appear that the data is leaning towards the 
use of ACE inhibitors in DM patients, as first line anti-hypertensive therapy, especially in light 
of their other proven benefits in DM patients (HOPE, 2000; Mann J, 2000; Hoogwerf & Young, 
2000). 
 
  1.1.2.4 Summary 
Addressing the complication of DM with appropriate lifestyle modification and pharmacotherapy 
are essential components in reducing the morbidity and mortality associated with type 2 DM. 
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optimal pharmacotherapy will continue to be reviewed and modified according to the ongoing 
results of large-scale trials. It is also clear that multifactorial interventions targeting lifestyle 
modification and appropriate pharmacotherapy are necessary in DM. Different race group have 
differences in rates of complications and response to pharmacotherapy (Gulliford & Mejia, 1999; 
UKPDS 55, 2001).  
